Month archive: October, 2020

New HSAP video: this is why strong health systems matter

The COVID-19 pandemic has shown what happens when countries’ health systems are unable to keep up with their populations’ public health needs. Malfunctioning, weak health systems need to be strengthened into responsive, well-functioning, properly staffed and sustainably financed systems. Not only for acute public health crises – but also to achieve access to sexual and reproductive health and rights (SRHR) for everybody, everywhere. With our partners in the Health Systems Advocacy Partnership (HSAP), we have made a video that explains this interconnectedness and emphasises that strong health systems should be a political priority.

Continue reading

Analysis and policy recommendations on the accountability at the EMA

Since the COVID-19 crisis has started, we have seen governments pressuring their own regulatory agencies to speed up the process of marketing authorisation. To make sure that this marketing authorisation process is done independently and transparently, the concept of accountability is key. Over the last year Wemos has conducted a qualitative analysis on the concept of accountability at the European Medicines Agency (EMA) and the perception hereof for different stakeholders in the process of marketing authorisation. Additionally, Wemos has looked into the risk of bias in Pre-Submission Activities (PSAs). This analysis lead to several policy recommendations in order to improve EMA’s accountability and to have better safeguards regarding risk of bias in PSAs.

Continue reading

Dutch Aid & Trade in health at odds with health equity

For the last 10 years, the Netherlands has been pursuing an Aid & Trade agenda. It combines development in low and middle-income countries (Aid) with the interests of Dutch companies and investors in these countries (Trade). The idea is to create a win-win situation. Our paper ‘In the interest of Health for All?’ shows that this agenda is also being rolled out in Africa’s health sector, strengthening the private-for-profit sector in healthcare delivery. We wanted to know what the Aid & Trade (A&T) policy instruments look like and what their impact is on health systems and progress towards universal health coverage (UHC).

Continue reading

Coronavirus test manufacturer Qiagen evades tax and benefits from public funding

New research by the Centre for Research on Multinational Corporations (SOMO) shows that the German coronavirus test producer Qiagen has been able to dodge millions of euros in tax since 2010 thanks to tax avoidance constructions in Ireland, Luxembourg, the US and Malta. Qiagen is one of the world’s leading producers of coronavirus test kits and is currently benefiting from mass orders from governments around the world. It is one of the major suppliers of COVID-19 test kits in the US. New SOMO research reveals that the biotech giant also received huge amounts of public funding from the US and the Netherlands, among others.

Continue reading

How COVID-19 test kit producer Qiagen receives public money but avoids taxes

New research by the Centre for Research on Multinational Corporations (SOMO) shows that the German coronavirus test producer Qiagen has been able to dodge millions of euros in tax since 2010 thanks to tax avoidance constructions in Ireland, Luxembourg, the US and Malta. Qiagen is one of the world’s leading producers of coronavirus test kits and is currently benefiting from mass orders from governments around the world. It is one of the major suppliers of COVID-19 test kits in the US. Wemos and SOMO reveal that the biotech giant also received huge amounts of public funding from the US and the Netherlands, among others.

Continue reading